Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivo-TIL in Metastatic Melanoma
NCT03374839Phase 2Unknown
- Sponsor
- CHU de Nantes
- Start
- Feb 2018
- Primary completion
- Jan 2024
- Modality
- Monoclonal Antibodies, Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of autologous tumor-infiltrating lymphocytes in melanoma, sponsored by CHU de Nantes. Status: unknown.
02
Drugs
autologous tumor-infiltrating lymphocytes
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT03374839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03374839.